A First-in-Human Study of CDK-002 (exoSTING) in Subjects with Advanced/Metastatic, Recurrent, Injectable Solid Tumors, with Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
Sponsor: |
Codiak BioSciences, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT4058 |
U.S. Govt. ID: |
NCT04592484 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to test the safety and dose of CDK-002 alone in subjects with cancer that is considered advanced and/or has spread to other parts of the body. CDK-002 is an investigational study drug that is being developed for the potential treatment of cancer. This is a first-in-human study. CDK-002 is a drug designed to activate the immune system so that it tries to kill cancer cells. CDK-002 will be injected directly into cancer tumors. This may be done using a CT scan or an ultrasound to help guide the injection. Cancers include breast cancer, head and neck/oral cancers, skin cancers, melanoma, and thyroid cancer.
This study is closed
Investigator
Matthew Ingham, MD
Are you at least 18 years old? |
Yes |
No |
Have you been diagnosed with an advanced or recurrent (comes back) solid tumor? |
Yes |
No |